CRISPR Therapeutics has its product; the bet now is one-time liver editing

The technology

CRISPR Therapeutics edits genes with CRISPR/Cas9. Its first product, Casgevy, edits a patient's own blood stem cells outside the body to treat sickle cell disease and transfusion-dependent beta thalassemia. It is approved in 39 countries and, since July 1, 2026, in the U.S. for patients aged 2 and older.

The newer bet is editing inside the body. CTX310 uses a lipid nanoparticle to switch off the ANGPTL3 gene in the liver. One infusion at 0.8 mg/kg cut LDL cholesterol 53% and triglycerides 48% on average at one year, according to ESC and NEJM data. The same delivery system carries CTX340 for hypertension and CTX460 for alpha-1 antitrypsin deficiency. Zugo-cel is an off-the-shelf CAR T therapy in autoimmune disease and lymphoma, and CTX611 is a Factor XI siRNA licensed from Sirius, per the Q2 report.

The odds

Casgevy has cleared approval risk. The rest of the pipeline is early. Under the BIO/Informa/QLS 2011 to 2020 study, only 7.9% of drugs entering phase 1 reach approval, and 52.0% of phase 1 programs move to phase 2. CTX310 has a strong phase 1a signal, but four patients at the top dose and wide ranges mean the phase 1b data matter. A drug that reaches phase 3 has a 52.4% chance of approval on those base rates.

Zugo-cel's lymphoma data, a 90% response rate at the top dose in large B-cell lymphoma as reported by Zacks, came from a small phase 1 group. Its autoimmune work is still in phase 1 with small numbers. CTX611 is in phase 2, where the same study puts the chance of reaching phase 3 at 28.9%.

The money

The company held $2,364.4 million in cash and investments on June 30, 2026, helped by $585.4 million in net proceeds from convertible notes sold in March. The second quarter net loss was $91.2 million. Casgevy revenue was $76 million in the quarter, but CRISPR's own revenue line was $10.2 million because Vertex books the sales and the two split profits.

The notes carry a 1.7308% coupon, mature in 2031 and convert at about $76.56 per share. The 10-Q says the company expects its cash to fund operations for at least 24 months. A planned global phase 3 for CTX611 would change that math.

The risks

Casgevy uptake depends on stem cell collection and chemotherapy conditioning, and all treated patients had grade 3 or 4 drops in blood counts, per the U.S. label summary. Growth will be limited by treatment center capacity.

In vivo editing is permanent. Any late liver safety signal in CTX310 would hit three programs that share the platform. Lilly's purchase of Verve Therapeutics puts a much larger company in one-time cardiovascular editing. On the people side, the CFO changed on October 19, 2026, an orderly internal promotion, but a change ahead of big spending decisions.

Our read

CRISPR has done what most gene editing companies have not: it has an approved product with rising sales and a balance sheet that does not force near-term dilution. The value case now rests on whether in vivo liver editing works as a one-time treatment for common diseases. The one-year CTX310 data are the best evidence so far, but the sample is small. The November AHA data will show whether a fixed dose gives consistent results. Until a program reaches phase 3, most of the pipeline carries early-stage failure rates, and Casgevy's split economics mean product growth reaches CRISPR's own accounts slowly.